Drug profile · INN
risankizumab-rzaa
SKYRIZI
risankizumab-rzaa (SKYRIZI) is a interleukin-23 inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — risankizumab-rzaa
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
risankizumab-rzaa (SKYRIZI) is a interleukin-23 inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Interleukin-23 inhibitor
Primary target: Interleukin-23
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
AbbVie Cerevel acquisition closes in $8.7B neuroscience deal
AbbVie completed its $8.7 billion acquisition of Cerevel Therapeutics, paying $45.00 per share in cash. The deal adds neuroscience assets as investors watch emraclidine, pipeline execution, and future filing catalysts.
AbbVie closes $8.7B Cerevel deal as neuroscience pipeline expands
AbbVie completed its $8.7 billion acquisition of Cerevel Therapeutics on August 1, 2024, after U.S. Federal Trade Commission review. The deal adds Cerevel assets to AbbVie’s neuroscience pipeline and sets up follow-on readouts to watch.
UCB's Bimzelx vs. AbbVie's Skyrizi: Psoriatic Arthritis Competitive Landscape
UCB's Bimzelx has demonstrated a competitive advantage over AbbVie's Skyrizi in head-to-head psoriatic arthritis trials. This analysis explores the implications for the competitive landscape and pharmaceutical business development.
UCB's Bimzelx Triumphs Over AbbVie's Skyrizi in Psoriatic Arthritis
UCB's Bimzelx has shown superior efficacy compared to AbbVie's Skyrizi in treating psoriatic arthritis, marking a significant milestone in the competitive landscape. This article analyzes the implications for pharmaceutical business development teams.
Related & competitor drugs
Frequently asked questions
What is risankizumab-rzaa?
risankizumab-rzaa (SKYRIZI) is a interleukin-23 inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for risankizumab-rzaa?
SKYRIZI is a marketed brand name for risankizumab-rzaa. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of risankizumab-rzaa?
risankizumab-rzaa has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.